Skip to Content

Cell>Point to Present Clinical Results in Cancer Molecular Imaging with SPECT at Society of Nuclear Medicine Annual Meeting June 7, 2010

CENTENNIAL, Colo.--(BUSINESS WIRE)--Jun 7, 2010 - Cell>Point announced today that it will present clinical results for its cancer imaging agent, 99mTc-EC-G, used to assess the efficacy of chemotherapy at the 2010 Society of Nuclear Medicine Annual Meeting on June 7, 2010.

99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine) is a SPECT (Single Photon Emission Computed Tomography) cancer imaging agent Cell>Point is developing as an alternative to FDG-PET (Fluorodeoxyglucose – Positron Emission Tomography) for diagnosing and staging patients with cancer.

In the reported study, Cell>Point enrolled seven patients with non-small cell lung cancer and receiving chemotherapy as part of a Phase I trial performed to assess dosimetry, biodistribution and pharmacokinetics of the agent. All patients were imaged with FDG-PET to assess the efficacy of chemotherapy. Investigators performed 99mTc-EC-G SPECT imaging to compare with PET findings.

Image interpretation showed a 1:1 correspondence between FDG-PET and 99mTc-EC-G SPECT for all primary lesions. For PET, all primary lesions had a fluffy appearance and were larger than noted on the pretreatment PET, consistent with chemotherapy inflammatory response. For

SPECT, the primary lesions were smaller and more discrete, with clinical findings of chemotherapy efficacy. Two patients had confirmed false-positive FDG-PET findings due to infection.

99mTc-EC-G shows promise for assessing the efficacy of chemotherapy during the course of therapy in this limited patient population,” said David Rollo, M.D., Ph.D., president of Cell>Point.

The oral presentation will be held on:

MONDAY, JUNE 7, 2010


  • No. 117 — Clinical results for 99mTc-EC-G as a target-specific imaging agent for NSCLC. David Rollo, Cell>Point, Saratoga, Calif.

About 99mTc-EC-G

99mTc-EC-G is the company's cancer and cardiovascular molecular imaging agent. It is the first product stemming from Cell>Point's EC Technology drug platform. More information on 99mTc-EC-G and EC Technology can be found at the Cell>Point website ( under Technology/Pipeline.

About Cell>Point

Cell>Point is a clinical-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart, and other diseases. Cell>Point has exclusive license to five drug-development platforms, all from The University of Texas M. D. Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point's drug candidates, recent press releases, and patents and patent filings can be obtained through its website at The company is headquartered in Centennial, Colo., and has additional offices in San Francisco and Houston.


Contact: Cell>Point
Terry Colip, 303-689-9693
Managing Member
Agency 33
Vincent Dipas, 303-591-7919


Posted: June 2010